SG47943A1 - N-alkyl-2-substituted atp analogues - Google Patents

N-alkyl-2-substituted atp analogues

Info

Publication number
SG47943A1
SG47943A1 SG1996005584A SG1996005584A SG47943A1 SG 47943 A1 SG47943 A1 SG 47943A1 SG 1996005584 A SG1996005584 A SG 1996005584A SG 1996005584 A SG1996005584 A SG 1996005584A SG 47943 A1 SG47943 A1 SG 47943A1
Authority
SG
Singapore
Prior art keywords
alkyl
independently represent
halogen
phenyl
atp analogues
Prior art date
Application number
SG1996005584A
Other languages
English (en)
Inventor
Peter Alan Cage
Anthony Howard Ingall
Nicholas David Kindon
Original Assignee
Astra Pharma Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939302636A external-priority patent/GB9302636D0/en
Priority claimed from GB939325712A external-priority patent/GB9325712D0/en
Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod
Publication of SG47943A1 publication Critical patent/SG47943A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG1996005584A 1993-02-10 1994-02-08 N-alkyl-2-substituted atp analogues SG47943A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939302636A GB9302636D0 (en) 1993-02-10 1993-02-10 Compounds
GB939325712A GB9325712D0 (en) 1993-12-16 1993-12-16 Compounds

Publications (1)

Publication Number Publication Date
SG47943A1 true SG47943A1 (en) 1998-04-17

Family

ID=26302434

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996005584A SG47943A1 (en) 1993-02-10 1994-02-08 N-alkyl-2-substituted atp analogues

Country Status (25)

Country Link
US (2) US5721219A (fr)
EP (1) EP0683789B1 (fr)
JP (1) JP3083156B2 (fr)
KR (1) KR100315612B1 (fr)
CN (1) CN1042430C (fr)
AT (1) ATE159950T1 (fr)
AU (1) AU679721B2 (fr)
CA (1) CA2155673C (fr)
CZ (1) CZ286050B6 (fr)
DE (1) DE69406649T2 (fr)
DK (1) DK0683789T3 (fr)
ES (1) ES2108425T3 (fr)
FI (1) FI110687B (fr)
GR (1) GR3025995T3 (fr)
HU (1) HU221501B (fr)
IL (1) IL108602A (fr)
NO (1) NO305209B1 (fr)
NZ (1) NZ261159A (fr)
PL (1) PL175623B1 (fr)
RU (1) RU2136693C1 (fr)
SG (1) SG47943A1 (fr)
SK (1) SK281309B6 (fr)
TW (1) TW326045B (fr)
UA (1) UA54366C2 (fr)
WO (1) WO1994018216A1 (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK281309B6 (sk) * 1993-02-10 2001-02-12 Astra Pharmaceuticals Limited N-alkyl-2-substituované adenozíntrifosfátové deriváty, spôsob ich prípravy, farmaceutické prostriedky obsahujúce tieto deriváty a použitie týchto derivátov
EP0929218A4 (fr) * 1996-10-30 2001-05-16 Univ North Carolina Antagonistes des recepteurs p2y
ID21635A (id) * 1996-12-20 1999-07-08 Astra Pharma Prod Komposisi farmasi untuk pengeringan beku
US6686462B2 (en) * 1997-02-28 2004-02-03 The Regents Of The University Of California Antiviral compounds and methods of administration
AU2003257524B2 (en) * 1997-07-11 2006-04-06 Astrazeneca Ab New formulation
SE9702680D0 (sv) * 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
FI104901B (fi) * 1997-10-20 2000-04-28 Leiras Oy Uudet metyleenibisfosfonihappojohdannaiset
US8586781B2 (en) 1998-04-02 2013-11-19 Mbc Pharma, Inc. Bone targeted therapeutics and methods of making and using the same
US6750340B2 (en) * 1998-04-02 2004-06-15 Mbc Research, Inc. Bisphosphonate conjugates and methods of making and using the same
US7598246B2 (en) * 1998-04-02 2009-10-06 Mbc Pharma, Inc. Bisphosphonate conjugates and methods of making and using the same
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US7205404B1 (en) * 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
US6303774B1 (en) 1999-08-20 2001-10-16 Sri International Nucleoside pyrophosphate and triphosphate analogs and related compounds
SE9903345D0 (sv) 1999-09-17 1999-09-17 Astra Pharma Prod Novel process
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
AR039558A1 (es) * 2000-08-21 2005-02-23 Inspire Pharmaceuticals Inc Composiciones y metodo para el tratamiento de glaucoma o hipertension ocular
US6897201B2 (en) 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
RU2004128943A (ru) * 2002-02-28 2005-04-20 Байота, Инк. (Us) Средства, имитирующие нуклеотиды, и их пролекарственные формы
AU2003248077A1 (en) * 2002-07-18 2004-02-09 Sankyo Company, Limited Medicinal composition for treating arteriosclerosis
US20050192245A1 (en) * 2002-07-18 2005-09-01 Sankyo Company, Limited Medicinal composition for treating arteriosclerosis
NZ539796A (en) 2002-11-21 2006-11-30 Kowa Co Peritoneal dialysis method comprising adenosine triphosphate
US8293890B2 (en) * 2004-04-30 2012-10-23 Advanced Cardiovascular Systems, Inc. Hyaluronic acid based copolymers
EP1604669A1 (fr) * 2004-06-10 2005-12-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation d'analogues de l'ATP pour le traitement de maladies cardiovasculaires
WO2009140092A1 (fr) 2008-05-13 2009-11-19 The Medicines Company Conservation de l'inhibition de plaquettes durant une thérapie anti-plaquettes
US8759316B2 (en) * 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) * 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) * 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
PT2498731T (pt) * 2009-11-11 2020-02-21 Chiesi Farm Spa Métodos de tratamento ou prevenção de uma trombose de endoprótese
WO2012100654A1 (fr) * 2011-01-26 2012-08-02 北京化工大学 Composé de ribofuranosyl-purine, procédé de préparation pour celui-ci, et utilisation de celui-ci
AU2012214396B2 (en) * 2011-02-09 2017-04-27 Chiesi Farmaceutici S.P.A. Methods for treating pulmonary hypertension
CA2843885C (fr) 2011-08-01 2020-03-10 Mbc Pharma, Inc. Derives a base de vitamine b6 de nucleotides, d'acyclonucleotides et de phosphonates d'acyclonucleosides
BR112015022070B1 (pt) 2013-03-09 2022-01-18 Chiesi Farmaceutici S.P.A. Uso de cangrelor
CN104447928A (zh) * 2013-09-13 2015-03-25 天津市汉康医药生物技术有限公司 坎格雷洛二水化合物
CN104447927A (zh) * 2013-09-13 2015-03-25 天津市汉康医药生物技术有限公司 坎格雷洛一水合物晶体及其制备方法
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
JP2017512183A (ja) 2014-02-13 2017-05-18 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
CN105273025B (zh) * 2014-07-22 2019-07-26 上海医药工业研究院 一种制备坎格雷洛的中间体及其制备方法和应用
EP3244900A4 (fr) 2015-01-14 2018-05-30 Chiesi Farmaceutici S.p.A. Formulations pharmaceutiques comprenant du cangrelor de haute pureté et leurs procédés de préparation et d'utilisation
CN105061431B (zh) * 2015-07-28 2017-03-29 山东百诺医药股份有限公司 6‑n‑（2‑（甲硫基）乙基）‑2‑（（3,3,3‑三氟丙基）硫代）‑9h‑嘌呤及其制备方法和应用
CN107001405B (zh) * 2015-11-06 2019-03-05 江苏恒瑞医药股份有限公司 制备坎格雷洛中间体的方法
CN107973798B (zh) * 2016-10-25 2020-04-24 上海医药工业研究院 2-[(3,3,3-三氟丙基)硫代]-6-氨基-9h-嘌呤及制法
CN107973832B (zh) * 2016-10-25 2021-11-12 上海医药工业研究院 6-n-[2-(甲硫基)乙基]-2-[(3，3，3-三氟丙基)硫代]腺苷的制法
CN106674322B (zh) * 2016-12-07 2019-04-16 上海博志研新药物技术有限公司 一种坎格雷洛中间体的纯化方法
WO2018185715A1 (fr) * 2017-04-06 2018-10-11 Msn Laboratories Private Limited, R&D Center Procédé amélioré pour la préparation d'un monoanhydride de l'acide n6-[2-(méthylthio)éthyl]-2-[(3,3,3-trifluoropropyl)thio]-5'-adénylique avec de l'acide (dichlorométhylène)bisphosphonique et de ses sels pharmaceutiquement acceptables
US11260071B2 (en) 2017-06-23 2022-03-01 Chiesi Farmaceutici S.P.A. Method of preventing of systemic-to-pulmonary-artery shunt thrombosis
WO2019092546A1 (fr) * 2017-11-10 2019-05-16 Olon S.P.A. Procédé efficace de préparation de cangrelor
CN109912674A (zh) * 2017-12-12 2019-06-21 亚宝药业集团股份有限公司 一种坎格雷洛四钠盐的制备方法
RU2020126177A (ru) 2018-01-09 2022-02-10 Лиганд Фармасьютикалз, Инк. Ацетальные соединения и их терапевтическое применение
US20190241606A1 (en) * 2018-02-05 2019-08-08 Scinopharm Taiwan, Ltd. Process for preparation of cangrelor tetrasodium and intermediate therefor
CN108033983B (zh) * 2018-02-09 2021-06-08 盐城锦明药业有限公司 一种2‐(3,3,3‐三氟丙基)硫代腺苷的合成方法
EP4289435A1 (fr) 2022-06-07 2023-12-13 Université de Liège Analogues atp n-alkyl-2-substitués pour utilisation comme agent antibactérien

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU764326A1 (ru) * 1977-11-16 1982-09-23 Ордена Ленина Институт Химической Физики Ан Ссср Способ получени спин-меченого производного аденозинтрифосфата
US5049550A (en) * 1987-11-05 1991-09-17 Worcester Foundation For Experimental Biology Diadenosine 5', 5'"-p1, p4,-tetraphosphate analogs as antithrombotic agents
CA2049977A1 (fr) * 1989-03-24 1990-09-25 Hirofumi Kitaoka Agent nootropique
EP0508687B1 (fr) * 1991-04-06 1995-09-13 Astra Pharmaceuticals Limited Analogues d'ADP
GB9107236D0 (en) 1991-04-06 1991-05-22 Fisons Plc Compounds
SK281309B6 (sk) * 1993-02-10 2001-02-12 Astra Pharmaceuticals Limited N-alkyl-2-substituované adenozíntrifosfátové deriváty, spôsob ich prípravy, farmaceutické prostriedky obsahujúce tieto deriváty a použitie týchto derivátov

Also Published As

Publication number Publication date
JPH08506335A (ja) 1996-07-09
FI953794A0 (fi) 1995-08-10
AU5977094A (en) 1994-08-29
SK99495A3 (en) 1996-02-07
HK1002936A1 (en) 1998-09-25
ES2108425T3 (es) 1997-12-16
FI110687B (fi) 2003-03-14
IL108602A (en) 1999-12-22
EP0683789B1 (fr) 1997-11-05
US5955447A (en) 1999-09-21
HUT72464A (en) 1996-04-29
CN1042430C (zh) 1999-03-10
TW326045B (en) 1998-02-01
CZ286050B6 (cs) 1999-12-15
DE69406649D1 (de) 1997-12-11
WO1994018216A1 (fr) 1994-08-18
PL310160A1 (en) 1995-11-27
DK0683789T3 (da) 1998-02-09
DE69406649T2 (de) 1998-03-05
NO953126D0 (no) 1995-08-09
UA54366C2 (uk) 2003-03-17
CA2155673A1 (fr) 1994-08-18
HU221501B (en) 2002-10-28
GR3025995T3 (en) 1998-04-30
KR100315612B1 (ko) 2002-06-20
EP0683789A1 (fr) 1995-11-29
NO953126L (no) 1995-09-28
US5721219A (en) 1998-02-24
SK281309B6 (sk) 2001-02-12
RU2136693C1 (ru) 1999-09-10
FI953794L (fi) 1995-08-10
CA2155673C (fr) 2004-08-17
JP3083156B2 (ja) 2000-09-04
ATE159950T1 (de) 1997-11-15
NO305209B1 (no) 1999-04-19
AU679721B2 (en) 1997-07-10
IL108602A0 (en) 1994-05-30
PL175623B1 (pl) 1999-01-29
CZ203295A3 (en) 1995-12-13
CN1119869A (zh) 1996-04-03
NZ261159A (en) 1997-06-24

Similar Documents

Publication Publication Date Title
HUT72464A (en) N-alkyl-2-substituted atp analogues
GB9211172D0 (en) Compounds
ZA919181B (en) Oxazolopyridine derivatives,processes for preparing these and pharmaceutical compositions containing them
HUP9802822A2 (hu) Halogén-benzimidazol-származékok, intermedierjeik, előállításuk és a vegyületeket hatóanyagként tartalmazó mikrobicid készítmények
PL308666A1 (en) Derivatives of 11,21-bisphenyl-19-norpregnan, method of obtaining them and pharmaceutical composition containing such derivatives
DE69330601D1 (de) Serotoninergische ergolin derivate
ES455741A1 (es) Un procedimiento para la preparacion de nuevos derivados de 1,3-bencenodimetanol.
HUP0204217A2 (en) Novel a-500359 derivatives
AU639154B2 (en) New imidazole compounds, a process for the preparation thereof, and pharmaceutical compositions containing them
ES435361A1 (es) Un metodo para la preparacion de nuevos esteres alcohilicosde aminoacidos.
GR3037045T3 (en) Pseudopeptides derived from neurokinines, process of preparation and pharmaceutical compositions comprising them
JO1825B1 (en) Therapeutic agents
MX9708525A (es) Derivados de vinilpirrolidinon-cefalosporina.
JO1648B1 (en) Nitrogen compounds